- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Cancer Moonshot Creates Hard Feelings With Some Researchers
What we're reading, February 1, 2016: some medical researchers disagree with sharing raw data used in their research; the medical community is torn on whether or not the annual checkup is worthwhile; and Donald Trump vows to extend healthcare coverage to the lower class.
While medical researchers agree in theory with Vice President Joe Biden’s cancer moonshot proposal, the idea of sharing raw data used in research has created dissension among the community, according to POLITICO. The trouble started when New England Journal of Medicine ran an op-ed pointing out that while data sharing was good, it could not be done by so-called “data parasites,” who would misuse work that took researchers years to assemble.
Physicians remain mixed on whether or not the annual checkup is a worthwhile endeavor. The annual checkup was once an unquestioned practice, but now it is being debated with some medical societies recommending against it for healthy adults. USA Today has highlighted some pros and cons of having routine checkups that may help consumers decide whether or not having one is right for them. Included in the lists is the fact that routine checkups provide an opportunity to fit in proven screening and prevention practices (pro) and that routine checkups waste time and money and can actually harm patients sometimes (cons).
Donald Trump continues to set himself apart from his Republican opponents. Although he remains vague on the details, the GOP frontrunner pledged to extend healthcare coverage to the lower class, reported The Hill. However, he denied that he was calling for a single-payer system, as rival Ted Cruz has said. Trump acknowledged that he might lose the election based on his vow.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
